• Home
  • Products & Services
    • VBS Pharmaceuticals
      • CAR Peptide Technology
      • CAR Peptide Applications
        • Co-administered Therapeutics
        • Pulmonary Hypertension
        • Sepsis
        • Gene Therapy
    • VBS Interventional
      • Interventional Technology
        • Endoarterial Biopsy Catheter
        • Endoarterial Biopsy Procedure
        • Endoarterial Biopsy Sequence
        • Endoarterial Biopsy Sample
        • Single Use Components
        • Endoarterial Biopsy Kit
      • Interventional Applications
        • Pulmonary Arterial Hypertension
        • Peripheral Vascular Disease
        • Lung Transplant Rejection
        • Vasculitis/Collagen Vascular Disease
        • Coronary Artery Disease
        • Critical Care Applications — Acute Lung Injury & Acute Respiratory Distress Syndrome
        • Lung Cancer
    • VBS Molecular Diagnostics
      • Molecular Diagnostics Technology
  • Product Pipeline
  • COVID-19
  • News
  • About VBS
    • Quality
    • VBS Team
    • VBS Board of Directors
  • VBS Scientific Articles
  • Investment
  • Contact

Investment page

VBS is currently seeking corporate partners, strategic investors, and accredited investors interested in sharing in the financial benefits to be accrued from the successful development of our products and services. Investment drives innovation of cutting edge technologies and increases our ability to provide much sought-after solutions for some of the most serious disease challenges in medicine today.

If you are interested in finding out more about investment opportunities at VBS please email us at: investment@vascularbiosciences.com

Latest News

  • Vascular BioSciences Will Present Results of “CAR Peptide Targeted Liposomes Loaded with an Admixture of Fasudil and DETA Nonoate for the Treatment of PAH”, and “A PAH Drug Ranking Strategy for Individualized Combination Therapy via Pulmonary Endoarterial Biopsy” at the American Thoracic Society International Conference in San Diego, California on May 22, 2024
  • Vascular BioSciences Announces Publication of “Intratracheally Administered Peptide-Modified Lipid Admixture Containing Fasudil and/or DETA NONOate Ameliorates Various Pathologies of Pulmonary Arterial Hypertension”
  • Vascular BioSciences Announces Publication of “A Bioinformatic Algorithm based on Pulmonary Endoarterial Biopsy for Targeted Pulmonary Arterial Hypertension Therapy” in the Current Issue of The Open Respiratory Medicine Journal 
  • Vascular BioSciences Announces Publication of “CAR Selectively Enhances the Pulmonary Vasodilatory Effect of Fasudil in a Microsphere Model of Pulmonary Hypertension” in the Current Issue of The Open Respiratory Medicine Journal
  • Vascular BioSciences Receives $2.7M STTR Fast-Track Grant for CAR Liposomes with VA Hospital of Northern California

Contact Us

For inquiries about investment in VBS, please contact us at investment@vascularbiosciences.com

  • Home
  • Products & Services
  • Product Pipeline
  • News
  • About VBS
  • VBS Scientific Articles
  • Investment
  • Contact Info
  • Privacy Policy